3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Motor Activity
20
Polycystic Ovary Syndrome
10
Prostatic Neoplasms
7
Breast Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
4
Insulin Resistance
3
Lung Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Cardiotoxicity
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Primary Dysautonomias
1
Pediatric Brain Tumor
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lymphoma, Follicular
1
Lupus Erythematosus, Systemic
1
Inflammation
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Diabetes Mellitus, Type 1
1
Chemotherapy-Related Cognitive Impairment
1
Cardiovascular Diseases
1
Interventions
Etanercept
12
Adalimumab
12
Infliximab
7
golimumab
4
Tumor Necrosis Factor Inhibitors
4
Certolizumab Pegol
4
Abatacept
4
tofacitinib
2
tocilizumab
2
Rituximab
2
Antirheumatic Agents
2
Vitamin D
1
Vaccines
1
Syringes
1
Surveys and Questionnaires
1
Standard of Care
1
Sodium Chloride
1
Saline Solution
1
Radioimmunodetection
1
Prednisone
1
Practice Guidelines as Topic
1
Phlebotomy
1
Observation
1
Nivolumab
1
Methotrexate
1
Methods
1
Lysine Acetyltransferase 5
1
Licensure
1
Leflunomide
1
Interviews as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Arthritis, Rheumatoid
×
High-Intensity Interval Training
×
Clear all
NCT05215509
2024-02-02
RABEX
Rigshospitalet, Denmark
Phase NA
Completed
69 enrolled